Enhancing sensitivity of target cells to CTL function through RT: implications for CAR T-cell efficacy and antigen escape. (A) Percentage of A20 tumor cells alive after RT, CAR T-cell, and RT and CAR T-cell treatments. (B) Flow cytometry for B220 and CD19 markers after in vitro treatment of A20 tumor cells with RT, CAR T-cell, and RT and CAR T-cell treatments. (C) B220⁺ and CD19⁺ alive cells after treatments. (D) B220⁺ alive cells after treatment with RT, CAR T cells, and T cells isolated from CT26 tumor–bearing mouse adoptively transferred with T cells from RT plus CAR T-cell donor. Graphs show the mean ± SEM. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. CTR, XXX.